Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

Author:

Beghetti Maurice1,Channick Richard N.2,Chin Kelly M.3,Di Scala Lilla4,Gaine Sean5,Ghofrani Hossein‐Ardeschir6,Hoeper Marius M.7,Lang Irene M.8,McLaughlin Vallerie V.9,Preiss Ralph4,Rubin Lewis J.10,Simonneau Gérald11,Sitbon Olivier11,Tapson Victor F.12,Galiè Nazzareno13

Affiliation:

1. Pediatric Cardiology UnitCentre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique, University of Geneva and Lausanne Lausanne Switzerland

2. David Geffen School of Medicine, University of California Los Angeles Los Angeles CA USA

3. Division of Internal MedicineUniversity of Texas Southwestern Dallas TX USA

4. Actelion Pharmaceuticals Ltd Allschwil Switzerland

5. National Pulmonary Hypertension UnitMater Misericordiae University Hospital Dublin Ireland

6. University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center of Lung Research, and Department of MedicineImperial College London London UK

7. Department of Respiratory MedicineHannover Medical School and German Centre for Lung Research Hannover Germany

8. Department of Internal Medicine II, Division of CardiologyMedical University of Vienna Vienna Austria

9. Department of Internal MedicineUniversity of Michigan Health System Ann Arbor MI USA

10. Department of MedicineUniversity of California San Diego CA USA

11. APHP, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs, CHU BicêtreUniversité Paris-Sud, Le Kremlin-Bicêtre Paris France

12. Division of Pulmonary and Critical Care Medicine, Department of MedicineCedars Sinai Medical Center Los Angeles CA USA

13. Department of Experimental, Diagnostic and Specialty Medicine (DIMES)Bologna University Hospital Bologna Italy

Funder

Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3